Podcasts about glioma

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the pros and cons of virtual neurology education, the FDA approval of tirzepatide for obesity-related obstructive sleep apnea, and the promise of AI for glioma assessment.  

In this episode of Brain Tumor Talk, we dive into the world of biomarker testing—a powerful tool in brain tumor diagnosis and treatment. With the 2021 World Health Organization (WHO) classification emphasizing the role of molecular biomarkers, understanding tumor profiling is more crucial than ever. Shwetal Mehta, PhD, and Charuta Furey, MD, join us on the episode to break down the science in an accessible way that empowers patients.Tune in to learn the essentials, so you're ready to discuss biomarker testing with your care team.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patients also received intracranial injections of the checkpoint inhibitor combination: nivolumab + ipilimumab. At the conference, Oncology Times reporter Peter Goodwin caught up with lead author of the study, Bart Neyns, MD, PhD, Head of Medical Oncology at the Vrije Universiteit Brussel in the University Hospital Brussels Faculty of Medicine & Pharmacy in Belgium.

Dr. Evan Noch interviews Drs. Pravesh Gupta and Krishna Bhat about their recent manuscript entitled "Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas", published online in Neuro-Oncology in August 2024 Read Paper

Article - The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists'Clinical Decision-Making in Patients With Posttreatment High-GradeGlioma: A Prospective Survey-Based Study Atefeh Zeinoddini, MD, discusses the AJR article by Dagher et al. exploring the impact of advanced neuroimaging on management decisions after treatment for high-grade glioma, based on surveys of neurooncologists.

Dr. Maya Graham interviews Drs. Mary Jane Lim-Fat and Kee Kiat Yeo about their recent manuscript entitled "A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients", published online in Neuro-Oncology in July 2024. Link: https://doi.org/10.1093/neuonc/noae142

Teri Gaberman's son Aaron was diagnosed with a rare form of Pediatric Brain Cancer when he was 10 years old in 2005. The next year Aaron contacted former New York Yankee great Bobby Murcer who had been diagnosed with a Glioma type of Brain Cancer at the end of 2006 and that started an incredible friendship which lasted until Bobby passed away on July 8th of 2008. Teri will talk about her son's amazing life and her Berni and Mercer non- profit which has helped and is helping so many in the Pediatric Cancer community.

Dr. Iyad Alnahhas interviews Dr. Linda Bi, Hia Ghosh and Ruchit Patel about their recent manuscript entitled: "Contemporary Prognostic Signatures and Refined Risk Stratification of Gliomas: An Analysis of 4400 Tumors", published online in Neuro-Oncology in August 2024. More Information: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noae164/7737688

Join us on "Brain Tumor Talk" as Dr. Nasser Yaghi, a neurosurgical oncology fellow at the Ivy Brain Tumor Center, shares his journey from a middle school student fascinated by surgery to pursuing a career as a neurosurgeon. Learn about the rigorous educational path from medical school to residency and the commitment required to excel in a neurosurgical fellowship, which includes an extra year of specialized training under a renowned neurosurgeon.In this episode, Dr. Yaghi delves into the day-to-day life of a neurosurgeon, discussing the challenges and rewards of diagnosing and treating brain tumors, performing complex surgeries, and having crucial conversations with patients. Tune in for valuable insights into the path to becoming a neurosurgeon.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

Weston Hermann was first diagnosed with a very rare form of a Glioma type of Pediatric Brain Cancer when he was 7 years old in 2014 and is now going through his 5th battle with this disease within the last 10 years. His father Jared will talk about the amazing fight that Weston has been through and that his resilience has allowed him to still be able to perform as a well known and well regarded 17 year old hockey player , despite playing many games while going through a chemotherapy regiment. 

With new advances in the treatment of brain cancer, patients have more options than ever. This week, Faith talks with Dr. Kathryn Beal, a radiation oncologist at NewYork-Presbyterian and Weill Cornell Medicine, to explore how breakthroughs in immunotherapy and stereotactic radiosurgery can successfully treat metastatic cancer in the brain. In recognition of Glioblastoma Awareness Day, Dr. Beal also explains treatment options for gliomas, and her hope for the future for patients with brain tumors and brain metastases.

Dr. Maya Graham interviews Dr. Martin van den Bent about his and his team's recent review article entitled "The biological significance of age, enhancement, extent of resection and tumor grade in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review", published online in Neuro-Oncology in

Listen to a soundcast of the April 23, 2024, FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Join us on "Brain Tumor Talk" as we sit down with Dr. Yoshie Umemura, Chief Medical Officer at the Ivy Brain Tumor Center, to dive into the complexities of brain tumor treatments. Dr. Umemura shares her expert insights on everything from the current standard of care and various chemotherapy protocols to the potential life-changing impact of clinical trials.In this episode, Dr. Umemura explains the array of available treatment options, including surgery, radiation, and clinical trials that offer new therapies not yet widely accessible. She emphasizes the importance of a strong patient-doctor partnership, guiding listeners on how to engage with their healthcare providers to make informed decisions tailored to their unique care needs.Discover why clinical trials are pivotal in advancing treatment and how they provide access to groundbreaking therapies while still maintaining quality of life during treatment. Learn what motivates Dr. Umemura to push the boundaries of conventional treatment and get a personal glimpse into her journey to becoming a leading neuro-oncologist.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

In this AJR Conversation, Carlos Zamora, MD, PhD speaks with Leland S. Hu, MD about his team's recently published article on the current status of advanced MRI and PET techniques for the post-therapeutic response assessment of high-grade adult-type gliomas.

Dr. Iyad Alnahhas interviews Drs. Alice Morin, Samuel Abbou and Brice Fresneau about their recent manuscript entitled "Very long-term outcomes of pediatric patients treated for optic pathway gliomas: a longitudinal cohort study" published online in Neuro-Oncology in March 2024. Read Paper

Dr. Stephen Bagley provides an overview of two enrolling clinical trials at Penn Medicine. The first explores targeted CAR T therapy in recurrent IDH wild-type glioblastoma; the second pairs two investigational drugs in the treatment-of recurrent IDH-mutant glioma.

VIsit Nascentmc.com for medical writing assistance. Visit learnamastyle.com for freebies on medical writing and editing and ChatGPT. - Fasenra Pediatric Asthma Expansion: No details provided for this update. - Beqvez for Hemophilia B: FDA approved gene therapy, Beqvez, for adults with moderate to severe hemophilia B, which enables the production of clotting protein factor IX. This one-time treatment by Pfizer, derived from Spark Therapeutics, aims to replace frequent infusion therapies, demonstrating superior efficacy in a late-stage trial. - Anktiva for Bladder Cancer: Anktiva received FDA approval for treating BCG-unresponsive non-muscle invasive bladder cancer, enhancing NK and T cell proliferation. Based on a trial with 77 patients, it showed a 62% complete response rate, surpassing international clinical benchmarks, leading to its designation as a breakthrough therapy. - Pivya for UTI: FDA approved pivmecillinam (Pivya) for treating uncomplicated urinary tract infections caused by specific bacterial strains. This marks the first new antibiotic for such infections in the U.S. in over 20 years, backed by effective outcomes in three clinical trials. - Tovorafenib for Pediatric Low-Grade Glioma: Tovorafenib was approved for pediatric low-grade glioma patients with specific BRAF alterations, showing a 67% response rate in the FIREFLY-1 trial. It has been designated for accelerated approval due to its potential in treating these brain tumors. - Entyvio Maintenance for Crohn's Disease: Vedolizumab (Entyvio) received approval for subcutaneous administration as Crohn's disease maintenance therapy after initial intravenous induction. Supported by the VISIBLE 2 Study, it proved effective in maintaining clinical remission at 52 weeks. - Alecensa for NSCLC: Alecensa was approved as an adjuvant treatment post-tumor resection for ALK-positive non-small cell lung cancer. In the ALINA trial, it significantly extended disease-free survival compared to chemotherapy, particularly in early-stage patients. - SPG601 for Fragile X Syndrome: The FDA cleared SPG601 for a phase 2a trial in Fragile X Syndrome, addressing synaptic function through BK channel activation. This marks an advance for treating the core symptoms of the most common inherited intellectual disability. - Lumisight for Visualizing Breast Cancer: The FDA approved Lumisight and the Lumicell Direct Visualization System for use during lumpectomy surgeries to detect residual cancer tissues. This system, shown in the INSITE trial, improves surgical outcomes by reducing the need for second operations. VIsit Nascentmc.com for medical writing assistance. Visit learnamastyle.com for freebies on medical writing and editing and ChatGPT.

Dr. Luca Szalontay,  Assistant Professor of Pediatrics at Columbia University Medical Center, discusses the work of Columbia's Initiative for Drug Delivery Innovation which is exploring new treatments for pediatric brain tumors utilizing Convection Enhanced Delivery and Focused Ultrasound. This initiative has launched a new clinical trial using Focused Ultrasound for patients with  progressive diffuse midline glioma (DMG)

Dr. Maya Graham interviews Dr. Joseph Costello about his and his team's recent manuscript entitled "Whole tumor analysis reveals early origin of the TERT promoter mutation and intracellular heterogeneity in TERT expression", published online in Neuro-Oncology in December 2023.

Description: Dr. Maya Graham interviews Dr. Carl Koschmann about his and his team's recent manuscript entitled: "Liquid biopsy in H3K27M diffuse midline glioma", published online in Neuro-Oncology in December 2023. Download PDF

BUFFALO, NY- January 31, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on January 24, 2024, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.” Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature oligodendrocytes as a possible source of gliomagenesis. Brain enriched myelin associated protein 1 (BCAS1) is a novel marker of immature oligodendrocytes and was proposed to contribute to tumorigenesis in non-central nervous system tumors. However, the role of BCAS1 in diffuse glioma is still underexplored. In this new study, researchers Raquel Morales-Gallel, María José Ulloa-Navas, Patricia García-Tárraga, Ricardo Prat-Acín, Gaspar Reynés, Pedro Pérez-Borredá, Luis Rubio, Vivian Capilla-González, Jaime Ferrer-Lozano, and José Manuel García-Verdugo from the University of Valencia-CIBERNED, Mayo Clinic, Hospital Universitari i Politècnic La Fe, University of Pablo de Olavide, and University of Seville-CSIC analyzed the expression of BCAS1 in different tumor samples from patients with diffuse gliomas (17 oligodendrogliomas; 8 astrocytomas; 60 glioblastomas) and uncovered the molecular and ultrastructural features of BCAS1+ cells by immunostaining and electron microscopy. “Our results show that BCAS1+ cells exhibit stellate or spherical morphology with similar ultrastructural features.” Stellate and spherical cells were detected as isolated cells in all studied gliomas. Nevertheless, only stellate cells were found to be proliferative and formed tightly packed nodules with a highly proliferative rate in oligodendrogliomas. Their findings provide a comprehensive characterization of the BCAS1+ cell population within diffuse gliomas. The observed proliferative capacity and distribution of BCAS1+ stellate cells, particularly in oligodendrogliomas, highlight BCAS1 as an interesting marker, warranting further investigation into its role in tumor malignancy. “In conclusion, this insight will shed light on the establishment of BCAS1 as a clinically relevant molecule, serving not only as a diagnostic or prognostic marker but also as a novel therapeutic target for the development of cutting-edge treatments.” DOI - https://doi.org/10.18632/oncotarget.28553 Correspondence to - José Manuel García-Verdugo - j.manuel.garcia@uv.es Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28553 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, brain tumor, diffuse glioma, oligodendroglioma, glioblastoma, BCAS1 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Dr. Iyad Alnahhas interviews Dr. Steven Tobochnik about his and his team's recent manuscript entitled "Glioma genetic profiles associated with electrophysiologic hyperexcitability", published online in Neuro-Oncology in Sep 2023. Read paper

Dr. Jasmin Jo interviews Dr. Harry Pinson about his and his team's recent manuscript entitled: "Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era" Read Paper

TWiN explains research showing that interaction between glioma cells and neurons in the brain shares mechanistic features with synaptic plasticity that contributes to memory and learning in the healthy brain.  Hosts: Vincent Racaniello, Jason Shepherd, and Timothy Cheung Subscribe (free): Apple Podcasts, Google Podcasts, RSS Links for this episode MicrobeTV Discord Server Glioma synapses recruit mechanisms of adaptive plasticity (Nature) Timestamps by Jolene. Thanks! Music is by Ronald Jenkees Send your neuroscience questions and comments to twin@microbe.tv

Max Pound was an outstanding young athlete and full of life until 2020 when  his mother Carol, who in her professional life was involved with early oncology drug development, noticed some concerning health signs and took Max to get them checked out. Shortly after that Max was diagnosed with Diffuse Hemispheric Glioma, a very rare form of Pediatric Brain Cancer at the age of 10. Through much of 2021 Max was feeling well enough to return to his athletic endeavors and to school when possible, but at the end of 2021 Max had a relapse, struggled through 2022 , and passed away on January 11th of 2023.Carol will talk about her beloved son and the Max Pound Foundation which her family started to honor Max's memory in 2023. 

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium's recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.Read the full Policy Review:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In July of 2022 Hayley and Justin Dickens came on to my podcast just two months after their daughter Kallie passed away from the Pediatric Brain Cancer Diffuse Midline Glioma. It is now 14 months since they both talked so beautifully about Kallie and on today's podcast Hayley and Justin will speak beautifully once again, detailing how they have been able to handle Kallie's passing and what they have accomplished in keeping her legacy more than alive and  at the forefront of their thoughts. 

Imagine you—or a loved one—receives a cancer diagnosis. Overnight, you find yourself trying to become an oncology expert, desperately looking for information about options. You stumble across a research paper that looks promising—if you could make sense of all the science-speak. Then you find Cancer.Net, the patient information website of Conquer Cancer and the American Society of Clinical Oncology (ASCO). This doctor-approved resource makes cancer terminology easier to digest and offers the latest guidelines on research and treatment. In this episode of Your Stories, host and cancer survivor Brenda Brody is joined by Dr. Jyoti Patel, a clinical oncologist and the editor-in-chief of Cancer.Net. Together, they unpack some of the year's biggest research breakthroughs, explain what makes these findings meaningful for patients, and talk about the long-term impact of donor-funded research. They also share why providing cancer information in lay terms is essential to raising awareness and support.

After being diagnosed with Neurofibromatosis 1 which can cause tumors to form, Addie Gould was diagnosed with an Optic Pathway Glioma, which is a form of Pediatric Brain Cancer. This caused great damage to Addie's eyesight in her left eye. On today's podcast  Addie's mother Jillian will talk about Addie's treatment ordeal which included a 60 week Chemotherapy cycle. Jillian will also discuss this week's Pan Mass Challenge Bicycle event, in which Addie will be the Pedal Partner for Team Kermit, under the captaincy of Steven Branfman, who lost his son Jared to cancer in 2005. 

Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Timothy Cloughesy, MD!

In this episode, Dr Antonio Silvani presents his editorial “New perspectives: glioma in adult patients”. The aim of this research is to consider some aspects of the diagnosis and treatment of adult gliomas and how innovations in diagnosis and therapy, including Artificial intelligence and Next-generation sequencing, are opening up new scenarios in approaching these tumors. Furthermore, dr Silvani highlights burden in the patients' quality of life of the postoperative treatment planning and follow-up. Link to the article https://journals.sagepub.com/doi/full/10.1177/03008916231159716

After experiencing headaches and vomiting through much of the summer in 2019, Lori Evans took her then 12 year old son Noah to the doctor and eventually to a Neurologist, who ordered an MRI which showed that Noah had the Pediatric Brain Cancer Diffuse Midline Glioma. After chemotherapy and radiation treatments, Noah was enrolled in the Clinical Trial ONC 201 which eventually stopped working and in January of 2021, Noah passed away after a gallant battle against this terrible disease.Lori will talk about her beloved son and about the Noah Brave Foundation, which helps families both monetarily and emotionally who are going through a similar situation to what the Evans family experienced.

Listen to a soundcast of the March 16, 2023, FDA approval of Tafinlar (dabrafenib) for pediatric patients with low-grade glioma with a BRAF V600E mutation

In this week's episode we'll discuss how azacytidine therapy influences the contributions of mutated HSC clones to hematopoiesis in MDS and CMML, learn more about the risk of venous thromboembolism in patients with adult-type diffuse glioma, and discuss the importance of 1p32 deletions as an independent and adverse prognostic factor in myeloma.

Does fasting during treatment make it work better? Does overnight fasting stave off recurrence? How does fasting affect cancer in general? Tina & Leah talk about the benefits (and risks!) of limiting food intake during and after cancer treatment. Links we mentioned on this episode and other cool stuff:Fasting alongside neoadjuvant chemotherapy in those with breast cancer (2013) Clinical trial on fasting during chemo, currently enrolling those with breast cancer (currently recruiting) Review of the “effect of fasting on cancer” (2022)Clinical trial that provides all meals and uses amino acid deprivation for those with colorectal cancer (FAETH) (Currently recruiting)Prolonged overnight fasting in breast cancer (2016) Conclusion: “Prolonging the length of the nightly fasting interval (>13 hours) may be a simple, nonpharmacologic strategy for reducing the risk of breast cancer recurrence.”Overnight fasting improves blood sugar control (2015) The chemo trial (10 patients) that started it all: fewer side effects with fasting! (2009)Into mechanisms? Here's some fasting biochemistry (2015) Glioma (glioblastoma) and fasting- you'll lose weight, but it could help too. (2021)Stage III low-grade follicular lymphoma regressed with fasting (2015)Protein restriction improves immunotherapy (2018)Amino acid depletion as therapy for cancers (2021)Potential metabolic targets in triple-negative breast cancer (2020)Rebecca Katz's Magic Mineral Broth recipeValter Longo, PhD - Originator of the Fasting Mimicking DietAutophagy - How cells recycle themselvesDr. Kaczor's article on methionine restriction and cancer growth & control (2015)Support the showSupport the podcast! Leave us a tip here.Or, go to Buymeacoffee. Either way, we will give you a shout-out! Find our podcast useful? We hope so! Join us! Please review & rate us! (every bit helps!)Share this podcast with someone you love! This link works great: https://podfollow.com/the-cancer-pod Email us: thecancerpod@gmail.comWe are @TheCancerPod Instagram Twitter Facebook THANK YOU!

Dr. Linda Douw discusses her paper, "Regional healthy brain activity, glioma occurrence, and symptomatology". Show references: https://academic.oup.com/brain/article/145/10/3654/6709376 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.    

Description: Dr. Maya Graham interviews Drs. Gaia Ninatti and Martina Sollini about their recent manuscript entitled: "Pre-operative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas", published online in Neuro-Oncology in September 2022. Full Report

Dear Johnny,My name is Mandy and I need some help this year. I'm not writing for myself, but my husband Tommy. We've been together for 8 years and actually got married in June. Tommy's had it rough these last few years. He was diagnosed in 2018 with a braintumor about the size of a grapefruit. He beat the odds and was out of the hospital from having it removed in 48 hours. He was also back to work within a month, and we thought we had this beat. In May, we were told he had 2 new tumors and we started radiation and chemo (Glioma brain tumors on left side of the brain). Soon after radiationhe had a stroke and a grand mal seizure. He works as a large machine mechanic in a factory and has continued to work as much as he can during treatment. He's continuing treatment and continuing to try and work. He is very proud and we aren't sure how much time he has. We feel like we've just been buying time. He has battled multiple brain tumors and still keeps going. He is just a fighter. The doctors say his health will continue deteriorating and even though they don't like to give a prognosis, they figure somewhere between 7 and 15 months. The reason I'm writing is because he will soon have to use a wheelchair and the basement area that is accessible isn't framed in or finished off for a wheelchair shower or proper flooring. I was able to install a sink and a toilet, but want it to be a comfortable area for him to live an fight this. I've been in contact with a contractor near us in St. Joe and have gotten a bid of $2000 to finish out the area, install the shower, frame it in, run the plumbing, do traction flooring and make everything wheelchair accessible. He has such a huge heart and has given all his life. I don't have the extra funds, but I would really like to do this for him. Thank you forreading my letter and happy holidays to all of you. – Mandy Who Helped: Robbie, Gene, George, Consentino's How You Helped: Raised money to help finish out the basement to make it wheelchair accessible, groceries

Frank Furnari, Ph.D., of UC San Diego, shares his work using stem cells as a vehicle to generate models of brain cancer. Focusing on glioblastoma, he explains how tumor avatars could lead to new therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38514]

Frank Furnari, Ph.D., of UC San Diego, shares his work using stem cells as a vehicle to generate models of brain cancer. Focusing on glioblastoma, he explains how tumor avatars could lead to new therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38514]

Frank Furnari, Ph.D., of UC San Diego, shares his work using stem cells as a vehicle to generate models of brain cancer. Focusing on glioblastoma, he explains how tumor avatars could lead to new therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38514]

Dr. Johan Koekkoek discusses his paper, "Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma". Show references: https://n.neurology.org/content/99/10/e999 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

When Eric Rodriguez was 15 years old, he was diagnosed with an Optic Glioma. A few years later, he developed lesions in his mouth which turned into Squamous Cell Carcinoma, a cancer that was found in his head and neck. Eric was able to go into remission for 13 years, but then his cancer returned and he passed away on December 29th of 2021. Eric's mother Anita will talk about the life that Eric led , the impact that he had on others,  and the legacy that he left behind. She will also discuss the Boston Marathon Jimmy Fund Walk, which is the largest participatory event that the Jimmy Fund sponsors.  This event will take place this Sunday October 2nd and Anita, family members, and friends, will be walking together as members of BEYOND CANCER to raise money in honor and memory of Eric.

Dr. Halley Alexander talks with Dr. Johan Koekkoek about the effectiveness of AED duotherapies in patients with glioma. Read the full article in Neurology. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Practical Radiation Oncology associate section editor Debra Nana Yeboa, MD, of MD Anderson Cancer Center, hosts a conversation on ASTRO clinical practice guideline on radiation therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma. Two of the guideline authors, Lia M. Halasz, MD, of University of Washington and Helen A. Shih, MD, MS, MPH, of Massachusetts General Hospital discuss the development process of the guideline and the evidence for the recommendations.

Vallerie “Val” Perrault, 32, sclerosing epithelioid fibrosarcoma, Wethersfield, CT, with Dr. Candace Haddox, Physician, Sarcomas, Dana-Farber Matilda "Tilly" Danoff, 3, spinal glioma, Somerville, with parents, Josh and Clare, and sister, Josephine (8) Stephanie Lafontaine, 41, breast cancer, Everett, with Dr. Filipa Lynce, Director, Inflammatory Breast Center, Dana-Farber

● Tilly broke her arm in June 2021, but it did not slow her down and she began goingby the moniker Tilly "The Destroyer." Accordingly, her favorite song that summerwas Metallica's "Seek and Destroy".● The break healed well on x-ray, but in late November her parents noticed she wasstill experiencing weakness in her arm. They saw an orthopedist and began asix-week physical therapy program, however, there did not seem to be any progress.An MRI, revealed that there was a tumor inside her cervical spinal cord, whichrequired surgery.● Tilly is currently undergoing treatment (Vinblastine) which has resulted in her tumorremaining stable. Tilly's treatment is slated to end July 20, with ongoing MRIs tomonitor the tumor and ensure that there is no growth.● Her doctors are Kee Kiat Yeo, MD, Pediatric Neuro-Oncology and Lev Gorfinkel, MD,Pediatric Hematology/Oncology Fellow. ● Tilly loves wearing costumes, especially on days she visits the clinic, and gives eachone a special name, like Barbara the Unicorn, Brucey the Monkey, Cow, and DoctorTilly.● Tilly and her family bring in donuts for the nurses and staff at the Jimmy Fund Clinicevery Wednesday, and Tilly brings a few extra for her friends at the clinic as well.When she is in the clinic on Wednesdays, people go out of their way to thank them.● Tilly loves the glitter they use for all of the kids' activities in the Jimmy Fund clinic,which they do such as waiting to get their vitals taken or port accessed, to see thedoctor, or get their chemotherapy.● Tilly's dad, Josh, was in the front seat of his car one day during the winter when helooked down and noticed glitter was on everything, days after Tilly's chemotherapytreatment. They now think of glitter as beautiful and lasting, with the power to covercancer, tumors, chemotherapy, and pain, and that dancing, jumping, reflections oflight and hope allows them to believe that we will all survive. Spinal glioma facts● Astrocytomas and gliomas are tumors that grow from brain cells called astrocytes.● These tumors can often develop in the cerebellum, the cerebrum, the brainstem, thehypothalamus, or the visual pathway.● These brain tumors are either classified as low-grade (grades I and II) or high-grade(grades III and IV) tumors. Children with low-grade tumors have a relatively favorableprognosis, especially when the tumors can be completely resected.● Survival rates depend on the child's specific type, location and grade of tumor;whether the tumor is localized; the child's age when diagnosed; and whether theastrocytoma is newly diagnosed or recurring.● Dana-Farber/Boston Children's houses the Pediatric Low-Grade Astrocytoma (PLGA)Program, the world's only multidisciplinary clinical and research program dedicatedto pediatric low-grade gliomas.● Established in 2007 with support from the PLGA Foundation, the program takes amultifaceted approach to finding more effective, less toxic treatments and a cure for children battling brain tumors and has become the standard bearer for the researchand care of pediatric brain tumors.

Addison Gould, 5, optic pathways glioma, Bourne, with mom, Jillian, and brother, Colin (7)

Matt and Jess go it alone this week and discuss a study looking at whether pesticide ingestion on fruit and vegetables increases the risk for glioma, they examine the rise […]